EP
PRCT icon

Essential Partners’s Procept Biorobotics PRCT Stock Holding History

Essential Partners’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.42K Sell
373
-1,635
-81% -$40.9K ﹤0.01% 1303
2026
Q1 		$50.2K Buy
2,008
+1,980
+7,071% +$55.8K 0.02% 604
2025
Q4 		$881 Sell
28
-63
-69% -$2.09K ﹤0.01% 2070
2025
Q3 		$3.25K Buy
91
+21
+30% +$959 ﹤0.01% 1602
2025
Q2 		$4.03K Buy
+70
New +$3.96K ﹤0.01% 1119

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Essential Partners's PRCT Position: Q2 2026 in Review

Essential Partners reduced its Procept Biorobotics (PRCT) stake by 81% in Q2 2026, selling an estimated $40.9K and leaving 373 shares worth $8.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1303.

Essential Partners first reported a position in PRCT in Q2 2025 and has held it in 5 quarters since. The position peaked at $50.2K in Q1 2026. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Essential Partners held 373 shares of Procept Biorobotics worth $8.42K as of Q2 2026.
  • Essential Partners sold 1,635 Procept Biorobotics shares in Q2 2026, an estimated $40.9K.
  • Procept Biorobotics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1303 holding.
  • Essential Partners first reported a position in Procept Biorobotics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Procept Biorobotics position peaked at $50.2K in Q1 2026.
  • 253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.